A Washington, D.C. law firm petitioned the U.S. Attorney’s Office in Boston to reopen an investigation of Forest Laboratories, claiming the company misrepresented clinical trial results used as the basis for Lexapro’s approval for pediatric use.
Source: Drug Industry Daily